PALO ALTO, Calif., Aug. 22 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that eight abstracts, including a clinical trial update session on anti-arrhythmia data from the MERLIN TIMI-36 study, have been accepted for presentation at the European Society of Cardiology (ESC) Congress 2007 taking place in Vienna, Austria from September 1-5, 2007.
A clinical trial update session entitled, The Effect of Ranolazine, a Novel Anti-anginal Agent with Electrophysiologic Properties, on the Incidence of Tachyarrhythmias: Results from the MERLIN-TIMI 36 Randomized Controlled Trial, is scheduled for presentation Wednesday, September 5 at 9:45 a.m. Central European Summer Time (CEST).
Other accepted abstracts include:
Ranexa(R) (ranolazine extended-release tablets):
Clinical Outcomes in Patients with Diabetes or the Metabolic Syndrome Presenting with Non- ST-elevation Acute Coronary Syndrome in the MERLIN- TIMI 36 Trial; Poster, Sunday, September 2, 8:30 a.m.-12:30 p.m. CEST
Cost of Angina:
Recurrent Angina Following Revascularization - Frequency, Patient Characteristics and Costs; Poster, Wednesday, September 5, 8:30 a.m. - 12:30 p.m. CEST
Late Sodium Current:
Reduction of Repolarization Reserve Unmasks the Role of Late Sodium Current in Rabbit Isolated Hearts; Poster, Sunday, September 2, 8:30 a.m. - 12:30 p.m. CEST
Mechanism of Ranolazine Block of Cardiac Na Channels; Poster, Monday, September 3, 2:00 - 6:00 p.m. CEST
Results from Two Randomized, Double-blind, Placebo-controlled Trials Evaluating the Safety of Regadenoson in Patients with Reactive Airways Disease; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST
Side Effect Profile and Tolerability of Regadenoson Myocardial Perfusion Scintigraphy in Women; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST
Superior Safety Profile of Regadenoson Versus Adenosine in Patients with Chronic Obstructive Pulmonary Disease Undergoing Radionuclide Myocardial Perfusion Imaging; Poster, Tuesday, September 4, 2:00 - 6:00 p.m. CEST
In addition, on Tuesday, September 4, CV Therapeutics is sponsoring an EBAC (European Board for Accreditation in Cardiology) educational program, Targeting Myocardial Ischaemia-Future Opportunities for Improved Outcomes, chaired by Dr. Phillip Poole-Wilson of the United Kingdom and Dr. Eugene Braunwald of the United States. On Monday, September 3, CV Therapeutics is sponsoring a FOCUS Cardiology Practice Session, Chronic Stable Angina Management.
Additional information regarding the ESC Congress 2007 can be accessed at http://www.escardio.org
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.
CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT- 6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.
|SOURCE CV Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved